All In Biotech

Free tool

FAERS Monitor: Slynd

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 211367 or its brand name (Slynd, Drospirenone). Reports on generic versions are filed under their own applications.

Reports

5,416

Serious

1,061

20% of reports

Hospitalization

307

Death reported

24

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • intermenstrual bleeding1,691
  • amenorrhoea863
  • heavy menstrual bleeding634
  • dysmenorrhoea389
  • product dose omission issue251
  • nausea231
  • product use in unapproved indication225
  • headache201
  • intentional dose omission199
  • wrong technique in product usage process181
  • fatigue169
  • menstruation irregular162
  • product prescribing issue157
  • off label use156
  • anxiety139

Reports by year received

View as table
YearReports
20052
20071
20082
20092
20108
20114
20124
20138
20142
20154
201610
20175
201820
201943
202095
2021131
2022402
2023936
20241,094
20251,316
20261,327

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,048,743 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
intermenstrual bleedingSignal1,6911683.81600.91,983,602
heavy menstrual bleedingSignal634294.3272.7172,082
amenorrhoeaSignal863200.9188.7163,189
dysmenorrhoeaSignal389117.4106.543,477
product prescribing issueSignal15728.224.14,064
intentional dose omissionSignal19927.323.84,986
menstruation irregularSignal16223.620.33,471
product use in unapproved indicationSignal2253.53.1409
wrong technique in product usage processSignal1813.53.0319
product dose omission issueSignal2513.32.9409
anxiety1391.91.659
headache2011.21.110
nausea2311.11.04
fatigue1690.80.75
off label use1560.70.622

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.